Bain Capital Life Sciences Investors, LLC - Dec 29, 2023 Form 3 Insider Report for NewAmsterdam Pharma Co N.V. (NAMS)

Role: 10%+ Owner
Signature: See signatures included in Exhibit 99.1
Stock symbol: NAMS
Transactions as of: Dec 29, 2023
Transactions value $: $0
Form type: 3
Date filed: 12/29/2023, 05:09 PM
Previous filing: May 30, 2023
Next filing: Jan 12, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	NAMS	Ordinary Shares						10.5M	Dec 29, 2023	See footnotes	F1, F3, F4, F5, F6, F7

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	NAMS	Warrant (right to buy)							Dec 29, 2023	Ordinary Shares	100K	$11.50	See footnotes	F2, F3, F4, F5, F6, F7

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents 5,376,356 Ordinary Shares held directly by BCLS Fund III Investments, LP ("BCLS Fund III"), 4,797,557 Ordinary Shares held directly by BCLS II Investco, LP ("BCLS II Investco"), 267,429 Ordinary Shares held directly by Bain Capital Life Sciences Fund II, L.P. ("BCLS Fund II") and 32,571 Ordinary Shares held directly by BCIP Life Sciences Associates, LP ("BCIPLS" and, together with BCLS Fund III, BCLS II Investco and BCLS Fund II, the "Bain Capital Life Sciences Entities").
F2	Represents a warrant to purchase 89,143 Ordinary Shares held directly by BCLS Fund II and a warrant to purchase 10,857 Ordinary Shares held directly by BCIPLS.
F3	Bain Capital Life Sciences III General Partner LLC ("BCLS III GP") is the general partner of Bain Capital Life Sciences Fund III, L.P. ("BCLS III"), which is the managing member of BCLS Fund III Investments GP, LLC ("BCLS Fund III GP"), which is the general partner of BCLS Fund III. As a result, each of BCLS III GP, BCLS III and BCLS Fund III GP may be deemed to share voting and dispositive power with respect to the securities held by BCLS Fund III. Each of BCLS III GP, BCLS III and BCLS Fund III GP disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.
F4	Bain Capital Life Sciences Investors II, LLC ("BCLSI II") is the general partner of BCLS Fund II. As a result, BCLSI II may be deemed to share voting and dispositive power with respect to the securities held by BCLS Fund II. BCLSI II disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.
F5	BCLS II Investco (GP), LLC ("BCLS II Investco GP"), whose managing member is BCLS Fund II, is the general partner of BCLS II Investco. As a result, each of BCLSI II, BCLS Fund II and BCLS II Investco GP may be deemed to share voting and dispositive power with respect to the securities held by BCLS II Investco. Each of BCLSI II, BCLS Fund II and BCLS II Investco GP disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.
F6	Boylston Coinvestors, LLC is the general partner of BCIPLS.
F7	Bain Capital Life Sciences Investors, LLC ("BCLSI") is the manager of each of BCLS III GP and BCLSI II and governs the investment strategy and decision making process with respect to investments held by BCIPLS. As a result, BCLSI may be deemed to share voting and dispositive power with respect to the securities held by the Bain Capital Life Sciences Entities. BCLSI disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.